Tesamorelin + CJC-1295 + Ipamorelin

This research blend combines three synthetic peptides — Tesamorelin, CJC-1295, and Ipamorelin — in a single vial containing 12mg total (6mg Tesamorelin, 3mg CJC-1295, 3mg Ipamorelin). The combination is studied for its convergent action on the growth hormone (GH) axis, pairing two structurally distinct GHRH receptor agonists with a selective ghrelin receptor agonist.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1-44), modified with a trans-3-hexenoic acid group attached to the N-terminus of the tyrosine residue. This modification confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation and extends plasma stability relative to native GHRH. Research has examined its role as a GHRH receptor agonist that stimulates endogenous pulsatile GH secretion, with particular focus in published literature on visceral adipose tissue, lipid metabolism, and IGF-1 signaling in clinical research models.

CJC-1295 (without DAC, also known as Mod GRF 1-29) is a synthetic tetra-substituted analog of GHRH 1-29. Four amino acid substitutions enhance enzymatic stability while preserving GHRH receptor binding activity. Research has investigated its role in stimulating pulsatile GH secretion from pituitary somatotrophs, with a short plasma half-life of approximately 30 minutes that preserves natural secretion rhythm.

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. Studies have highlighted its selectivity — stimulating GH release with minimal effect on cortisol, prolactin, or ACTH, distinguishing it from earlier secretagogues such as GHRP-2 and GHRP-6 studied in the literature.

The combination is studied because the three peptides target complementary pathways: Tesamorelin and CJC-1295 act on the GHRH receptor through different structural approaches, while Ipamorelin acts on the ghrelin receptor. The dual-GHRH approach is less common in research blends than the typical CJC-1295/Ipamorelin pairing and is investigated for potential differences in pulse amplitude and duration of somatotroph stimulation.

Research areas exploring this combination include:

• Pulsatile growth hormone secretion dynamics
• GHRH and ghrelin receptor pharmacology
• GH/IGF-1 axis signaling
• Comparative GHRH analog pharmacokinetics
• Somatotroph receptor crosstalk and synergy
• Visceral adipose tissue and lipid metabolism models
• Body composition and metabolic regulation research
• Peptide combination pharmacology

Product Specifications

• Peptides: Tesamorelin + CJC-1295 (no DAC) + Ipamorelin
• Quantity: 6mg Tesamorelin + 3mg CJC-1295 + 3mg Ipamorelin (12mg total per vial)
• Tesamorelin: GHRH 1-44 analog with N-terminal trans-3-hexenoic acid modification, 44 amino acids
• CJC-1295 (no DAC): Modified GHRH 1-29 analog, 30 amino acids
• CJC-1295 modifications: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions
• Ipamorelin sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (pentapeptide)
• Purity: ≥98% (HPLC verified)
• Form: Lyophilized powder
• Storage: Store at -20°C, protect from light and moisture; reconstituted solutions refrigerated

Disclaimer: This product is intended for laboratory and research purposes only. It is not a drug, food, or cosmetic, and is not intended for human or animal consumption, diagnostic use, or therapeutic application.